{"id":"W2997722341","doi":"10.3747/co.26.5085","title":"Preferences of Canadian Patients and Physicians for Adjuvant Treatments for Melanoma","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Trametinib; Dabrafenib; Pembrolizumab; Melanoma; Adverse effect; Family medicine; Regimen; Internal medicine; Adjuvant; Quality of life (healthcare); Cancer; Oncology; Vemurafenib; Metastatic melanoma; Immunotherapy; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004111737,0.00008096886,0.0002552175,0.0001979281,0.00003054297,0.0000029279,0.00003301893,0.00004674118,0.00003327236],"category_scores_gemma":[0.00002480155,0.00006818106,0.00005465867,0.00006530611,0.00002500855,0.00001675208,0.00001171025,0.00003228452,0.000007309348],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001197866,"about_ca_system_score_gemma":0.00008764899,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007713764,"about_ca_topic_score_gemma":0.007125541,"domain_scores_codex":[0.9994522,0.00001215179,0.0001454451,0.0001680773,0.00005358054,0.0001685648],"domain_scores_gemma":[0.999594,0.00006040323,0.0000790242,0.00008889829,0.00009283823,0.00008489073],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000689288,0.0008229327,0.1144862,0.0004437059,0.0002555372,0.000001283609,0.000680788,0.000001383118,0.0005452545,0.0005878308,0.01076005,0.8707257],"study_design_scores_gemma":[0.007527497,0.007949265,0.07538803,0.00007606467,0.0003794556,0.000006423376,0.0003026951,0.0003927865,0.000826709,0.0002441167,0.906783,0.0001239297],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931893,0.0001634281,0.00005370199,0.0003590443,0.001088393,0.002058339,0.0001123294,0.00001080499,0.002964666],"genre_scores_gemma":[0.9982713,0.0001019686,0.0002832433,0.0001160648,0.00005902815,0.0001735827,0.0001239486,0.00000933645,0.0008614881],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.896023,"threshold_uncertainty_score":0.3976219,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06610240493853994,"score_gpt":0.3426464521618954,"score_spread":0.2765440472233555,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}